Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Anticipate generic drug launch
Manage your formulary budget
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers|
|Abstract:||A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.|
|Inventor(s):||Liotta; Dennis C. (Stone Mountain, GA), Schinazi; Raymond F. (Decatur, GA), Choi; Woo-Baeg (North Brunswick, NJ)|
|Assignee:||Emory University (Atlanta, GA)|
|Filing Date:||Aug 20, 2003|
|Claims:||1. A method for the resolution of a mixture of the enantiomers of 2-hydroxylmethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC), which has the structure ##STR00001## comprising the steps of: (i) providing the mixture of the enantiomers as an 5'-O-acylated derivative of the structure ##STR00002## wherein R is an acyl group; (ii) exposing the 5'-O-acylated derivative of 2-hydroxylmethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane to an enzyme selected from the group consisting of Amano PS-800 lipase and .alpha.-chymotrypsin under conditions that allow selective hydrolysis of the 5'-O-acyl group; and (iii) separating the 5'-O-hydrolyzed enantiomer from the 5'-O-unhydrolyzed enantiomer. |
2. The method according to claim 1, wherein the enzyme is Amano PS-800.
3. The method according to claim 1, wherein the enzyme is .alpha.-chymotrypsin.
4. The method of claim 1, wherein R is a residue of an alkyl carboxylic acid selected from the group consisting of acetic acid, propionic acid, butyric acid and pentanoic acid.
5. The method of claim 1, wherein R is a residue of a halo-substituted alkyl carboxylic acid selected from the group consisting of 2-chloropropionic acid, 2-chlorobutyric acid and 2-chloropentanoic acid.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.